Globally recognised as a first-line standard of care, the public funding of ERBITUX® (cetuximab) [1] marks an important development for people living with left-sided RAS wild-type and BRAF wild-type ...

Globally recognised as a first-line standard of care, the public funding of ERBITUX®(cetuximab)[1] marks an important development for people living with left-sided RAS wild-type and BRAF wild ...

Pharmac will improve access to three cancer medicines from 1 November. The three medicines are cetuximab (branded as Erbitux) for bowel cancer, bendamustine for relapsed or refractory chronic ...

"Just as we learned that cetuximab (Erbitux) is inferior to cisplatin, we are now seeing that de-escalation based on our typical criteria is inferior to standard of care," she added. "The bar for ...

Associate Health Minister with responsibility for Pharmac David Seymour is pleased to see Pharmac continue to increase availability of medicines for ...

Specifically, evorpacept is being tested in combination with Cetuximab and Pembrolizumab for the treatment of colorectal cancer, with Venetoclax and Azacitidine for acute myeloid leukemia, and with ...

Cardiff has presented preclinical data in wild type mCRC, i.e. without a RAS mutation, showing that the combination of onvansertib and cetuximab led to tumor regression in 90% of the 20 models.

For example, RAS mutations activate signalling pathways that are downstream of the epidermal growth factor receptor (EGFR), rendering EGFR inhibitors such as cetuximab inactive. Second ...

Now, thanks to a Cancer Research UK trial, he’s enjoying playing football with his grandson. “It was March 2012 when I first ...

Pfizer, Inc. gained FDA approval in December 2020 for BRAFTOVI (encorafenib) plus cetuximab to manage patients with brafv600e ...

State Key Laboratory of Oral Disease & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Office of Cellular and Tissue-Based Products, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan; Office of Regulatory Science Research, Pharmaceuticals and Medical Devices Agency, Tokyo ...